Application of emerging toxicity screens in drug discovery: Challenges and implications

Future Medicinal Chemistry

Volumn 1, Issue 7, 2009, Pages 1201-1205

  Wilson, Alan G E ^a   Liu, Xuemei ^a   Kramer, Jeffrey A ^a  

^a LEXICON PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POTASSIUM CHANNEL HERG;

APOPTOSIS; CELL GROWTH; CELL PROLIFERATION; COMPUTER MODEL; DNA DAMAGE; DNA REPAIR; DRUG SAFETY; DRUG SCREENING; EDITORIAL; ENDOPLASMIC RETICULUM STRESS; HEAT SHOCK RESPONSE; HORMONE RESPONSE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MITOCHONDRIAL TOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; TOXICITY TESTING;

APOPTOSIS; DNA DAMAGE; DNA REPAIR; DRUG EVALUATION, PRECLINICAL; DRUG INDUSTRY; DRUG TOXICITY; ENDOPLASMIC RETICULUM; ETHER-A-GO-GO POTASSIUM CHANNELS; HIGH-THROUGHPUT SCREENING ASSAYS; ORPHAN NUCLEAR RECEPTORS; OXIDATIVE STRESS; PHARMACEUTICAL PREPARATIONS; TOXICITY TESTS;

EID: 77953453981     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.09.108     Document Type: Editorial

References (42)

1. Wiebel FJ, Andersson TB, Casciano DA et al. Genetically engineered cell lines: characterisation and applications in toxicity testing. The report and recommendations of ECVAM workshop 26. Altern. Lab. Anim. 25, 625-639 (1997).
2. Hasspieler BM, Haffner GD, Adeli K. In vitro toxicological methods for environmental health testing. Rev. Environ. Health. 11, 213-227 (1996).
3. Adams CP, Brantner VV. Estimating the cost of new drug development: is it really million dollars? Health Aff. 25, 420-428 (2006).
4. Helma C, Cramer T, Kramer S, De Raedt L. Data mining and machine learning techniques for the identification of mutagenicity inducing substructures and structure activity relationships of noncongeneric compounds. J. Chem. Inf. Comput. Sci. 44, 1402-1411 (2004).
5. Helma C. Data mining and knowledge discovery in predictive toxicology. SAR QSAR Environ. Res. 15, 367-383 (2004).
6. Dearden JC. In silico prediction of drug toxicity. J. Comput. Aided Mol. Des. 17, 119-127 (2003).
7. Judson R, Richard A, Dix DJ et al. The toxicity data landscape for environmental chemicals. Environ Health Perspect. 117, 685-695 (2009).
8. Kohen R, Nyska A. Oxidation of biological systems: oxidative stress phenomena, antioxidants, redox reactions, and methods for their quantification. Toxicol. Pathol. 30, 620-650 (2002).
9. Apel K, Hirt H. Reactive oxygen species: metabolism, oxidative stress, and signal transduction. Annu. Rev. Plant Biol. 55, 373-399 (2004).
10. Spector A. Review: Oxidative stress and disease. J. Ocul. Pharmacol. Ther. 16, 193-201 (2000).
11. Will Y, Hynes J, Ogurtsov VI, Papkovsky DB. Analysis of mitochondrial function using phosphorescent oxygen-sensitive probes. Nat. Protoc. 1, 2563-2572 (2006).
12. Neupert W, Herrmann JM. Translocation of proteins into mitochondria. Annu. Rev. Biochem. 76, 723-749 (2007).
13. Ernster L, Schatz G. Mitochondria: a historical review. J. Cell Biol. 91(Suppl.), S227-S255 (1981).
14. Schroder M. Endoplasmic reticulum stress responses. Cell Mol. Life Sci. 65, 862-894 (2008).
15. Marciniak SJ, Ron D. Endoplasmic reticulum stress signaling in disease. Physiol. Rev. 86, 1133-1149 (2006).
16. Xu C, Bailly-Maitre B, Reed JC. Endoplasmic reticulum stress: cell life and death decisions. J. Clin. Invest. 115, 2656-2664 (2005).
17. Kultz D. Molecular and evolutionary basis of the cellular stress response. Annu. Rev. Physiol. 67, 225-257 (2005).
18. Hartwell LH, Weinert TA. Checkpoints: controls that ensure the order of cell cycle events. Science 246, 629-634 (1989).
19. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 266, 1821-1828 (1994).
20. Kaufmann WK, Paules RS. DNA damage and cell cycle checkpoints. FASEB J. 10, 238-247 (1996).
21. Hiom K. DNA repair: a riddle at a doublestrand break. Curr. Biol. 19, R331-R333 (2009).
22. Cohn MA, D'Andrea AD. Chromatin recruitment of DNA repair proteins: lessons from the fanconi anemia and double-strand break repair pathways. Mol. Cell. 32, 306-312 (2008).
23. Altieri F, Grillo C, Maceroni M, Chichiarelli S. DNA damage and repair: from molecular mechanisms to health implications. Antioxid. Redox Signal. 10, 891-937 (2008).
24. Sheikh MS, Hollander MC, Fornance AJ Jr. Role of Gadd45 in apoptosis. Biochem. Pharmacol. 59, 43-45 (2000).
25. Wible BA, Hawryluk P, Ficker E, Kuryshev YA, Kirsch G, Brown AM. HERG-Lite: a novel comprehensive high-throughput screen for drug-induced hERG risk. J. Pharmacol. Toxicol. Methods. 52, 136-145 (2005).
26. Priest BT, Bell IM, Garcia ML. Role of hERG potassium channel assays in drug development. Channels 2(2) (2008).
27. Yao X, Anderson DL, Ross SA et al. Predicting QT prolongation in humans during early drug development using hERG inhibition and an anaesthetized guinea-pig model. Br. J. Pharmacol. 154, 1446-1456 (2008).
28. Giguere V. Orphan nuclear receptors: from gene to function, Endocr. Rev. 20, 689-725 (1999).
29. Kliewer SA, Willson TM. Regulation of xenobiotic and bile acid metabolism by the nuclear pregnane X receptor, J. Lipid Res. 43, 359-364 (2002).
30. Nebert DW. Drug-metabolizing enzymes in ligand-modulated transcription. Biochem. Pharmacol. 47, 25-37 (1994).
31. Elcombe CR, Odum J, Foster JR et al. Prediction of rodent nongenotoxic carcinogenesis: evaluation of biochemical and tissue changes in rodents following exposure to nine nongenotoxic NTP carcinogens. Environ. Health Perspect. 110, 363-375 (2002).
32. Hoel DG, Haseman JK, Hogan MD, Huff J, McConnell EE. The impact of toxicity on carcinogenicity studies: implications for risk assessment. Carcinogenesis 9, 2045-2052 (1988).
33. Tennant RW, Elwell MR, Spalding JW, Griesemer RA. Evidence that toxic injury is not always associated with induction of chemical carcinogenesis. Mol. Carcinog. 4, 420-440 (1991).
34. Aranda A, Pascual A. Nuclear hormone receptors and gene expression. Physiol. Rev. 81, 1269-1304 (2001).
35. Coecke S, Ahr H, Blaauboer BJ et al. Metabolism: a bottleneck in in vitro toxicological test development. The report and recommendations of ECVAM workshop 54. Altern. Lab Anim. 34, 49-84 (2006).
36. Olson H, Betton G, Robinson D et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul. Toxicol. Pharmacol. 32, 56-67 (2000).
37. Zambrowicz BP, Sands AT. Knockouts model the 100 best-selling drugs - will they model the next 100? Nat. Rev. Drug Discov. 2, 38-51 (2003).
38. MacDonald J, French JE, Gerson RJ et al. The utility of genetically modified mouse assays for identifying human carcinogens: a basic understanding and path forward. The Alternatives to Carcinogenicity Testing Committee ILSI HESI. Toxicol. Sci. 77, 188-194 (2004).
39. Baryla UM, Fleming JS, Stanton HC. The anesthetized ferret, an in vivo model for evaluating inotropic activity: effects of milrinone and anagrelide. J. Pharmacol. Methods. 20, 299-306 (1988).
40. Faiola B, Falls JG, Peterson RA et al. PPAR a, more than PPAR d, mediates the hepatic and skeletal muscle alterations induced by the PPAR agonist GW0742. Toxicol. Sci. 105, 384-394 (2008).
41. Mannisto PT, Kirkland D, Viluksela M, Tikkanen L. Toxicological studies with dithranol and its 10-acyl analogues. Arch. Toxicol. 59, 180-185 (1986).
42. Preston J, Hoffmann G. Casarett and Doull's Toxicology. McGraw Hill, Berkshire, UK (2001).